Seres Therapeutics, Inc. (MCRB) Shares Bought by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL raised its position in Seres Therapeutics, Inc. (NASDAQ:MCRB) by 162.4% during the first quarter, Holdings Channel reports. The firm owned 50,188 shares of the biotechnology company’s stock after buying an additional 31,062 shares during the period. Tudor Investment Corp ET AL’s holdings in Seres Therapeutics were worth $566,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Highbridge Capital Management LLC increased its stake in Seres Therapeutics by 104.0% in the first quarter. Highbridge Capital Management LLC now owns 30,843 shares of the biotechnology company’s stock worth $347,000 after buying an additional 15,726 shares during the period. Bank of America Corp DE increased its position in shares of Seres Therapeutics by 88.7% in the first quarter. Bank of America Corp DE now owns 23,948 shares of the biotechnology company’s stock valued at $270,000 after buying an additional 11,256 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of Seres Therapeutics by 5.1% in the first quarter. Schwab Charles Investment Management Inc. now owns 91,049 shares of the biotechnology company’s stock valued at $1,027,000 after buying an additional 4,446 shares during the last quarter. Citadel Advisors LLC increased its position in shares of Seres Therapeutics by 74.8% in the first quarter. Citadel Advisors LLC now owns 20,662 shares of the biotechnology company’s stock valued at $233,000 after buying an additional 8,841 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Seres Therapeutics by 5.8% in the first quarter. Geode Capital Management LLC now owns 166,325 shares of the biotechnology company’s stock valued at $1,874,000 after buying an additional 9,060 shares during the period. Hedge funds and other institutional investors own 75.54% of the company’s stock.

Shares of Seres Therapeutics, Inc. (MCRB) opened at 11.14 on Monday. The stock’s market capitalization is $449.94 million. Seres Therapeutics, Inc. has a one year low of $8.05 and a one year high of $35.98. The company’s 50-day moving average is $10.29 and its 200-day moving average is $10.15.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.63) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.02. Seres Therapeutics had a negative net margin of 441.10% and a negative return on equity of 68.86%. The business had revenue of $3.02 million for the quarter, compared to analysts’ expectations of $3 million. During the same period in the prior year, the company posted ($0.50) EPS. The business’s revenue for the quarter was up 11.9% on a year-over-year basis. On average, equities research analysts anticipate that Seres Therapeutics, Inc. will post ($2.63) earnings per share for the current year.

WARNING: This piece was originally published by WKRB News and is owned by of WKRB News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.wkrb13.com/markets/2285004/seres-therapeutics-inc-mcrb-shares-bought-by-tudor-investment-corp-et-al.html.

Several equities research analysts have issued reports on the stock. FBR & Co reissued an “outperform” rating and issued a $18.00 price objective on shares of Seres Therapeutics in a research report on Monday, March 20th. Zacks Investment Research raised shares of Seres Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 price target for the company in a research report on Wednesday, July 5th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Seres Therapeutics in a research report on Tuesday, March 21st. Canaccord Genuity set a $20.00 price target on shares of Seres Therapeutics and gave the stock a “buy” rating in a research report on Thursday, May 4th. Finally, Cowen and Company reiterated a “buy” rating on shares of Seres Therapeutics in a research note on Friday, May 19th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Seres Therapeutics has a consensus rating of “Buy” and an average price target of $21.50.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Want to see what other hedge funds are holding MCRB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Seres Therapeutics, Inc. (NASDAQ:MCRB).

Institutional Ownership by Quarter for Seres Therapeutics (NASDAQ:MCRB)

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2285004/seres-therapeutics-inc-mcrb-shares-bought-by-tudor-investment-corp-et-al.html

Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.